Assessment of oxidative stress in chronic pancreatitis patients

Mariette Verlaan, Hennie MJ Roelofs, Annie van Schaik, Geert JA Wanten, Jan BMJ Jansen, Wilbert HM Peters, Joost PH Drenth

AIM: To assess the levels of antioxidant capacity and oxidative damage in blood of chronic pancreatitis (CP) patients in comparison with those in healthy control subjects, by using different analytical techniques.

METHODS: Thirty-five CP patients and 35 healthy control subjects were investigated prospectively with respect to plasma levels of thiols, ferric reducing ability of plasma (FRAP, i.e. antioxidant capacity), levels of protein carbonyls and thiobarbituric acid reactive substances (TBARS). Additionally, we evaluated the production of reactive oxygen species (ROS) in whole blood.

RESULTS: The antioxidative thiols including cysteine, cysteinylglycine and glutathione were significantly lower in CP patients. In addition, the non-enzymatic antioxidant capacity was significantly lower in CP patients, which correlated with the amount of oxidative protein (protein carbonyls) and the extent of lipid damage (TBARS), both were significantly higher in CP patients. The ROS production in whole blood after stimulation with phorbo12-myristate 13-acetaat, demonstrated a strong tendency to produce more ROS in CP patients.

CONCLUSION: Oxidative stress may contribute to the pathogenesis of chronic pancreatitis by decreasing antioxidant capacity and increasing oxidative damage in CP patients may be a rationale for intervention with antioxidant therapy.

© 2006 The WJG Press. All rights reserved.

Key words: Chronic pancreatitis; Oxidative stress; Thiols; Ferric reducing ability of plasma; Protein carbonyls; Thiobarbituric acid reactive substances; Reactive oxygen species

INTRODUCTION

Chronic pancreatitis (CP) is a progressive irreversible inflammatory disease that eventually leads to an impaired exocrine and/or endocrine function of the pancreas. Although most cases have been attributed to alcohol abuse, the underlying causes of CP appear to be multi-faceted, including environmental as well as genetic factors. Chronic pancreatitis shares risk factors with pancreatic cancer such as smoking and alcohol abuse, but itself is also a risk factor for pancreatic adenocarcinoma. A genetic predisposition to pancreatitis is supported by the identification of sequence alterations in the genes encoding cationic trypsinogen (PRSS1), the cystic fibrosis transmembrane conductance regulator (CFTR), and the serine protease inhibitor, Kazal type 1 (SPINK1) in patients with hereditary pancreatitis. Additionally, an increased frequency of SPINK1 mutations has been reported in patients with alcohol-related chronic pancreatitis. So far we have not completely understood the pathogenesis of CP. Different hypotheses have been proposed, including the contribution of oxidative stress of endogenous origin or chemical stress by environmental or lifestyle-related xenobiotics. There is growing recognition that an imbalance between reactive oxygen species (ROS) producing and ROS scavenging processes leads to the damage of pancreatic acinar cells, initiating auto-digestion of the entire pancreas. This insight is suggested by data from experimental and clinical studies. Oxidative stress may be important in the pathogenesis of ethanol-induced pancreatic injury, although radiation, exposure to cigarette smoke, medication or trauma may stimulate the generation of free radicals, which subsequently may result in damage of lipids, proteins or nucleic acids. Activation of (enzymatic) antioxidant defence has been described in pancreatic disease independent of its origin. Glutathione and cysteine are important mediators in the defence against oxidative stress and both molecules play a key role in the maintenance of cellular thiol redox status. Therefore, in the present study the concentrations of glutathione, cysteine and other thiols were measured in blood plasma of patients with CP.

http://www.wjgnet.com/1007-9327/12/5705.asp
and healthy control subjects. In addition, we also measured the non-enzymatic antioxidant capacity by applying the ferric reducing ability of plasma (FRAP) assay in patients with CP and healthy controls. Further assessment of the level of oxidative stress was performed by measuring the concentrations of protein carbonyls in plasma in order to determine the amount of oxidative protein damage. As an indicator of lipid peroxidation we established the concentrations of thiobarbituric acid-reactive substances (TBARS). Finally, we investigated the generation of ROS by chemiluminescence in whole blood of both patients and controls.

MATERIALS AND METHODS

Subjects
The study was approved by the local medical ethical review committee and all subjects gave their written informed consent. This study was conducted at the Department of Gastroenterology of the University Medical Centre Nijmegen, the Netherlands and all subjects studied were Caucasians of Dutch extraction. A total of 35 consecutive CP patients were recruited between January 2004 and June 2004 at the out-patient clinic of the department. In 29 patients an alcohol-related etiology was indicated (the sum of reduced-, oxidised- and protein-bound thiols) cysteine, homocysteine, cysteinylglycine and glutathione with CP and healthy controls. Further assessment of the non-enzymatic antioxidant capacity by applying the ferric reducing ability of plasma (FRAP) assay in patients with CP and healthy controls. Further assessment of the level of oxidative stress was performed by measuring the concentrations of protein carbonyls in plasma in order to determine the amount of oxidative protein damage. As an indicator of lipid peroxidation we established the concentrations of thiobarbituric acid-reactive substances (TBARS). Finally, we investigated the generation of ROS by chemiluminescence in whole blood of both patients and controls.

Analysis of thiols
Samples of blood were taken by venapuncture into EDTA tubes. Whole blood was centrifuged at 1500 × g for 10 min within 1 h after collection and plasma was stored at -30°C until analysis. Concentrations of the thiols including cysteine, homocysteine, cysteinylglycine and glutathione (the sum of reduced-, oxidised- and protein-bound thiols) in plasma were quantified using high performance liquid chromatography (HPLC) with fluorescent detection, essentially as described by Fortin et al. and modified by Raijmakers et al. Thiol levels were calculated using four-point calibration curves for each thiol, which were run in parallel with the samples, and values were expressed in μmol/L.

Analysis of FRAP
The antioxidant capacity in blood plasma was measured using the ferric reducing ability of plasma (FRAP) assay, according to the method of Benzie and Strain. The reduction of ferric to ferrous ion at low pH formed a coloured ferrous-tripiprydyltriazine complex. Absorbance changes were linear over a wide concentration range with antioxidant mixtures, including plasma. FRAP values were obtained using a seven-point calibration curve of known amounts of Fe²⁺ and expressed in mmol Fe²⁺/L.

Analysis of protein carbonyls
The amount of oxidative protein damage, as a marker for oxidative stress, was determined using an enzyme linked immunosorbsent assay (ELISA) for estimation of protein carbonyls in body fluids, as essentially described by Buss et al. and adapted by Zusterzeel et al. Samples were incubated with dinitrophenylhydrazine and then adsorbed to wells of an ELISA plate before probing with a commercial antibody raised against protein-conjugated dinitrophenylhydrazine. The binding of biotin-conjugated primary antibody was then quantified after incubation with streptavidin-biotinylated horseradish peroxidase and staining with o-phenylenediamine. Calibration took place using oxidised and fully reduced albumin, and carbonyl levels were expressed in μmol/g protein.

Analysis of TBARS
Thiobarbituric acid-reactive substances (TBARS), mainly malondialdehyde (MDA) in plasma were evaluated by recording the fluorescence spectrum between 500 and 600 nm on a Shimadzu RFF-5000 spectrofluorometer, of the thiobarbituric acid-malonaldehyde complex, as described by Conti et al. Levels of TBARS were expressed in μmol MDA/L.

Analysis of ROS
ROS production in whole blood was evaluated using luminal-enhanced chemiluminescence, as measured in an automated LB96V Microlumat Plus Luminometer (EG & G Berthold, Belgium). Briefly, the signal-amplifying molecule luminol reacts with oxygen species (mainly superoxide anion) generated by neutrophils in whole blood, to produce an excited state intermediate that emits light as it returns to its ground state. ROS production was determined in the absence of a cellular stimulator, as well as in the presence of either a receptor-dependent (serum-treated zymosan, STZ) or a receptor-independent stimulus (phorbol 12-myristate 13-acetaat, PMA). Freshly obtained heparinized blood was 1:100 diluted in HBSS containing 1 mmol/L calcium. Two hundred μL of this diluted blood was added to each well of a 96-well plate. In addition, reaction mixtures contained 0.45 g/L bovine serum albumin (BSA), 0.83 mmol/L luminol and either 1 g/L STZ, 0.4 mg/L PMA or no stimulating agents. As an internal positive control for the luminescence process, samples of 1 g/L ammonium persulphate (APS) in phosphate-buffered...
solution (PBS) were run simultaneously. Chemiluminescence was monitored every 60 s for 1 h. EDTA blood, taken together with the heparinized blood samples, was tested for leukocyte counts and differentiation, in order to adjust the chemiluminescence produced during one hour (‘area under the curve’) in relative light units (RLU) per cell for neutrophil counts. All measurements were performed in quadruplicate and corrected for background values (absence of a stimulus). Opsonized zymosan particles were prepared by incubation of STZ with pooled human serum for 30 min at 37 °C, as previously described[25]. These particles were then washed twice in PBS and finally suspended at 12.5 g/L in PBS.

**Statistical analysis**

Data were analysed using SPSS version 12.0. Differences in the baseline characteristics of patients and controls were estimated with Fisher’s exact test and Student’s t-test. The Mann–Witney U-test was used to estimate differences in a non-parametrical manner. Differences were considered significant if \( P < 0.05 \). Finally, we examined the correlation between the non-enzymatic antioxidant capacity with the amount of oxidative protein and lipid damage in CP patients, using Spearman rank correlation test.

**RESULTS**

The characteristics of patients with CP and healthy controls are denoted in Table 1. The mean age of the CP patients was 51 years (range 25 to 74 years) and was not significantly different from that of the healthy controls (45 years; range 27 to 68 years). There was no significant difference in the distribution of gender between CP patients and healthy control subjects. Smoking habits between CP patients and healthy controls were not different; 66% of the patients and 63% of the control subjects smoked or stopped smoking within the last 5 years.

The oxidative stress was measured in CP patients and healthy controls. The plasma concentrations of cysteine (Cys), homocysteine (Hcy), cysteinylglycine (CGS) and glutathione (GSH), the plasma antioxidant capacity (FRAP) as well as the plasma levels of protein carbonyls and TBARS and chemoluminescence in whole blood are depicted in Table 2.

The plasma concentrations of antioxidative thiols including cysteine, cysteinylglycine and glutathione were significantly lower in the CP patients than in the controls (\( P = 0.021, P = 0.003 \) and \( P = 0.048 \), respectively). The plasma levels of homocysteine were similar in both groups. The antioxidant capacity as measured by the FRAP assay was also significantly lower in the CP patients than in the healthy control subjects (\( P < 0.001 \)). The levels of both carbonyls and TBARS were significantly higher in the CP patients than in the healthy controls (\( P < 0.001 \)). The chemoluminescence of diluted whole blood of CP patients and controls was not different, although there was a strong trend towards an increased ROS production after stimulation with PMA (\( P = 0.058 \)). As expected, spontaneous generation of ROS in the absence of a stimulus was less than 10% of the amount of ROS measured in response to the stimuli of PMA and STZ. The leukocyte counts and differentiation within the ranges were considered normal at our hospital. The values obtained with either assay were not different in patients with ACP and HCP.

In addition, the correlation between the non-enzymatic antioxidant capacity with the amount of oxidative protein and lipid damage in CP patients was examined and a negative correlation was found between the non-enzymatic antioxidant capacity and the amount of oxidative protein damage (\( n = -0.44, P = 0.013 \)), as well as between the non-enzymatic antioxidant capacity and the amount of lipid damage (\( n = -0.39, P = 0.004 \)). Finally, we found a positive correlation between oxidative protein and lipid damage (\( n = 0.67, P = 0.001 \)).

**DISCUSSION**

Alcohol abuse is regarded as a major risk factor for the development of CP. However, the exact mechanism behind the effect of alcohol remains unknown. Some evidence obtained by animal studies, suggests that metabolism of ethanol catalysed by cytochrome P4502E1 (CYP2E1) may contribute to oxidative stress in the pancreas during chronic alcohol consumption[19]. Trauma, exposure to radiation, cigarette smoke, medication or other toxins generating free

---

**Table 1  Main characteristics of patients with chronic pancreatitis and healthy controls**

| Characteristic | CP patients | Controls |
|---------------|-------------|----------|
| n             | 35          | 35       |
| Gender        |             |          |
| Male/Female   | 17/18       | 18/17    |
| Mean age (yr) | 51(25-74)   | 45 (27-68) |
| Smoking       |             |          |
| Yes/No        | 23/12       | 22/13    |

**Table 2  Thiol plasma concentrations, FRAP antioxidant capacity, protein carbonyl plasma levels, TBARS plasma levels and ROS production in whole blood of patients with CP and controls mean (range)**

| Measure for oxidative stress | CP patients | Controls |
|------------------------------|-------------|----------|
| Cys (μmol/L)                 | 225 (124-314)\( ^{*} \) | 249 (212-328) |
| Hcy (μmol/L)                 | 13.6 (5.0-38.2) | 12.7 (0.2-27.8) |
| CGS (μmol/L)                 | 34.8 (23.5-124) | 39.5 (25.2-56.7) |
| GSH (μmol/L)                 | 7.5 (2.4-18.5) | 8.9 (3.5-16.1) |
| FRAP (mmol Fe\(^{2+}\)/L)   | 0.75 (0.31-1.73) | 0.99 (0.69-1.57) |
| Carbonyls (μmol/mg protein)  | 0.32 (0.02-1.47) | 0.04 (0.01-0.07) |
| TBARS (μmol/L)               | 4.98 (0.23-27.79) | 0.35 (0.04-0.68) |
| ROS production (RLU/10\(^{6}\) cells) | 40 (1-83) | 33 (1-87) |
| PMA-stimulated               | 124 (11-266) | 111 (9-2330) |
| STZ-stimulated               | 225 (124-314)\( ^{*} \) | 249 (212-328) |

\(^{*}\)Cysteine; \(^{+}\)Homocysteine; \(^{\dagger}\)Cysteinylglycine; \(^{\ddagger}\)Glutathione; \(^{\circ}\)Ferric reducing ability of plasma; \(^{\ast}\)Thiobarbituric acid-reactive substances; \(^{\circ\circ}\)Reactive oxygen species; \(^{\circ\circ\circ}\)Thorbor 12-myristate 13-acetate; \(^{\circ\circ\circ\circ}\)Serum treated zymosan. \( P < 0.05 \) vs control.
radicals also may increase the amount of oxidants. In the present study, we assessed the antioxidant capacity and levels of oxidative damage in CP patients as compared with healthy controls by means of several analytical techniques that are known to measure various components that together constitute oxidative stress. The major observations were that plasma concentrations of some thiols, having antioxidant properties, were significantly lower in CP patients. Likewise the non-enzymatic antioxidant capacity as measured by the FRAP assay, was significantly lower in CP patients than in healthy control subjects. This inferior antioxidant capacity in CP patients parallels significantly increased amounts of oxidative protein and lipid damage, whereas the generation of ROS in whole blood did not show a statistically significant difference between CP patients and healthy control subjects, with a similar age and gender distribution and smoking habits. Our results clearly indicate that oxidative stress is present in patients with CP and that this eventually might contribute to the initiation and maintenance of inflammation in CP patients, as has been previously suggested. Thiols such as cysteine and glutathione play an essential role as antioxidants, and are involved in protein synthesis, redox sensitive transduction signalling, cell growth and proliferation, xenobiotic metabolism and immune regulation. Glutathione is conjugated to many xenobiotics and essential for the optimal functioning of numerous enzymes and hence crucial for cell viability. Decreased levels of glutathione in plasma have been reported, but paradoxically also increased glutathione levels may be found as a result of outshoot after enhanced synthesis due to oxidative stress or conjugation of toxic compounds, as has been shown in different disorders. We found significantly lower plasma concentrations of cysteine, cysteinylglycine and glutathione in CP patients as compared to healthy controls, whereas the control values measured here can be considered normal for the Dutch population. We found no elevated concentrations of homocysteine in CP patients, however homocysteine does not always act as an antioxidant, moreover elevated plasma concentrations of homocysteine are positively associated with an increased risk of cerebral, coronary or peripheral vascular diseases. In parallel with the lower plasma concentrations of the antioxidative thiols, the FRAP assay also demonstrated a significantly lower antioxidant capacity in CP patients. Since the FRAP assay does not measure sulfhydryl (SH)-containing antioxidants such as the thiols glutathione and cysteine, this indicates that other non-thiol related antioxidants are decreased in CP patients also. In patients with acute pancreatitis very low ascorbate concentrations in plasma have been described.

Protein carbonyl derivatives are generated by direct oxidative attack of proteins or by indirect lipid peroxidation products and therefore represent a good biomarker for general oxidative stress. The lower FRAP levels in CP patients are accompanied with high protein carbonyl concentrations, indicating that increased oxidative damage occurs as a result of the lower protective capacity as measured by FRAP. Former studies have demonstrated elevated plasma protein carbonyls in experimental animal models and humans with acute pancreatitis. Unless properly scavenged, ROS may lead to lipid peroxidation, which represents an important manifestation of oxidative stress. Lipid peroxidation is initiated when free radicals interact with polyunsaturated fatty acids. For instance, in cell membranes this may result in a chain reaction forming lipid hydroperoxides. Analysis of TBARS in plasma is a widely used method for the estimation of lipid peroxidation. In accordance with the elevated levels of protein carbonyls and lower antioxidant capacity, we found significantly increased plasma concentrations of TBARS in CP patients. The production of ROS, as measured in whole blood by chemiluminescence assay, was not significantly higher in CP patients than in healthy controls, although there was a strong trend to generate higher amounts of ROS after stimulation with PMA. We used luminol-enhanced chemiluminescence assay in 100-fold diluted whole blood to study ROS generation of peripheral blood cells in a non-disturbed system. As expected, ROS generation in the absence of a stimulus in CP patients was low, and not significantly different from the values in the healthy control group. Chemiluminescence measurements did not demonstrate a significantly increased ROS generation in CP patients, while the other analytical techniques applied here showed increased oxidative stress and damage in CP patients as compared to healthy control subjects, demonstrating that the oxidative damage in CP patients is caused by other reactive (oxygen) species rather than by leukocytes. Since most of the CP patients included in this study were alcoholics, the cause of oxidative damage might be mainly of exogenous origin. However, a contribution of oxidative stress of endogenous origin might also be possible, since we detected a strong tendency to produce ROS in CP patients after stimulation with PMA. This PMA-induced respiratory burst is receptor-independent and not absolutely dependent on priming, whereas priming does moderately influence the STZ-induced respiratory burst.

We measured the ROS production in whole blood and it is known that during isolation of neutrophils, these cells often become primed. The clinical importance of oxidative stress in human pancreatic disease was first suggested by Braganza et al., and subsequently supported by data from other groups, showing increased levels of lipid hydroperoxides in pancreatic juice and increased spontaneous production of ROS by neutrophils. The assessment of oxidative stress in CP patients corroborates the hypothesis that oxidative stress leads to damage of pancreatic acinar cells, initiating autodigestion of the entire pancreas as has been shown in the present study.

In summary, significantly higher levels of products of oxidative damage (protein carbonyls and TBARS), correlating with decreased levels of cysteine, cysteinylglycine, glutathione and non-enzymatic antioxidant capacity (FRAP) can be found in CP patients. Oxidative stress, defined as the imbalance between prooxidant and antioxidant capacity, is higher in CP patients, which may justify further studies on intervention with antioxidant therapies for this serious disease.
ACKNOWLEDGMENTS

The authors gratefully acknowledge Dr. EMJ van der Logt for her help with the cholinolinescence assay.

REFERENCES

1 Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, Landt O, Becker M. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000; 25: 213-216

2 Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001; 120: 682-707

3 Drenth JP, te Morsche R, Jansen JB. Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis. Gut 2002; 50: 687-692

4 Jansen JB, te Morsche R, van Goor H, Drenth JP. Genetic basis of chronic pancreatitis. Scand J Gastroenterol Suppl 2002; 91-94

5 Lowenfels AB, Maisonneuve P, Lankisch PG. Chronic pancreatitis and other risk factors for pancreatic cancer. Gastroenterology Clin North Am 1998; 27: 673-85, x

6 Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, Martin SP, Amann ST, Toskes PP, Liddle R, McGrath K, Uomo G, Post JC, Ehrlich GD. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996; 14: 141-145

7 Sharer N, Schwarz M, Malone G, Howarth A, Painter J, Super M, Braganza J. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998; 339: 645-652

8 Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998; 339: 653-658

9 Witt H, Luck W, Becker M, Bohmig M, Kage A, Truninger K, Drenth JP, Luck W, Becker M, Bohmig M, Kage A, Truninger K. Oxidative stress in chronic pancreatitis. Scand J Gastroenterol 2002; 37: 2761-2767

10 Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N Engl J Med 1995; 332: 1482-1490

11 Bulger EM, Helton WS. Nutrient antioxidants in gastrointestinal diseases. Gastroenterol Clin North Am 1998; 27: 403-419

12 Schoenberg MB, Birk D, Beger HG. Oxidative stress in acute and chronic pancreatitis. Am J Clin Nutr 1995; 62: 1305S-1314S

13 Ulrich AB, Schmied BM, Matsuzaki H, Lawson TA, Friess H, Andresen-Sandberg A, Buchler MW, Pour PM. Increased expression of glutathione S-transferase-pi in the islets of patients with primary chronic pancreatitis but not secondary chronic pancreatitis. Pancreas 2001; 22: 388-394

14 Santini SA, Spada C, Bononi F, Foschia F, Mutignani M, Perri V, Giardina B, Silveri NG, Costamagna G. Liver, pancreas and biliary tract enhanced lipoperoxidation products in pure pancreatic juice: evidence for organ-specific oxidative stress in chronic pancreatitis. Dig Liver Dis 2003; 35: 888-892

15 Seicenan A, Grigorescu M. The pathogenesis of chronic alcoholic pancreatitis. Rom J Gastroenterol 2002; 11: 19-24

16 Matsumura N, Ochi K, Ichimura M, Mizushima T, Harada H, Harada M. Study on free radicals and pancreatic fibrosis--pancreatic oxidative stress: protection by phospholipid repletion. Free Radic Biol Med 1995; 28: 1659-1664

17 Mathew P, Wylie R, Van Lente F, Steffen RM, Kay MH. Antioxidants in hereditary pancreatitis. Am J Gastroenterol 1996; 91: 1558-1562

18 Wallig MA. Xenobiotic metabolism, oxidant stress and chronic pancreatitis. Focus on glutathione. Digestion 1998; 59 Suppl 4: 13-24

19 Nordt ID, Aptel MV, Lux O, Haber PS, Pirola RC, Wilson JS. Chronic ethanol administration causes oxidative stress in the rat pancreas. J Lab Clin Med 1998; 131: 442-446

20 Simovic MO, Bonham MJ, Abu-Zidan FM, Windsor JA. Man-
respiratory burst in human granulocytes. A Ca\(^{2+}\)-dependent and a Ca\(^{2+}\)-independent route. *J Immunol* 1989; 142: 623-628

45 Tool AT. Priming and activation of human granulocytes. University of Amsterdam, The Netherlands. 1996, Thesis

46 Kuijpers TW, Tool AT, van der Schoot CE, Ginsel LA, Onderwater JJ, Roos D, Verhoeven AJ. Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. *Blood* 1991; 78: 1105-1111

47 Braganza JM, Scott P, Bilton D, Schofield D, Chaloner C, Shiel N, Hunt LP, Bottiglieri T. Evidence for early oxidative stress in acute pancreatitis. Clues for correction. *Int J Pancreatol* 1995; 17: 69-81

48 Szuster-Ciesielska A, Daniluk J, Kandefer-Szwerszen M. Alcohol-related cirrhosis with pancreatitis. The role of oxidative stress in the progression of the disease. *Arch Immunol Ther Exp (Warsz)* 2001; 49: 139-146